The osteogenic and angiogenic potential of microRNA-26a delivered via a non-viral delivery peptide for bone repair

• Published in: Journal of controlled release Vol. 362; pp. 489 - 501
• Main Authors: Chambers, Phillip, Ziminska, Monika, Elkashif, Ahmed, Wilson, Jordan, Redmond, John, Tzagiollari, Antzela, Ferreira, Cole, Balouch, Auden, Bogle, Jasmine, Donahue, Seth W., Dunne, Nicholas J., McCarthy, Helen O.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.10.2023
• Subjects: Bone; Calvarial defect; DNA; microRNA; miR26a; Nanoparticle; Osteogenesis; RALA peptide; Calvarial defect; Nanoparticle; DNA; microRNA; miR26a; RALA peptide; Bone; Osteogenesis
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2023.09.006

Bone-related injuries and diseases are among the most common causes of morbidity worldwide. Current bone-regenerative strategies such as auto- and allografts are invasive by nature, with adverse effects such as pain, infection and donor site morbidity. MicroRNA (miRNA) gene therapy has emerged as a promising area of research, with miRNAs capable of regulating multiple gene pathways simultaneously through the repression of post-transcriptional mRNAs. miR-26a is a key regulator of osteogenesis and has been found to be upregulated following bone injury, where it induces osteodifferentiation of mesenchymal stem cells (MSCs) and facilitates bone formation. This study demonstrates, for the first time, that the amphipathic, cell-penetrating peptide RALA can efficiently deliver miR-26a to MSCs in vitro to regulate osteogenic signalling. Transfection with miR-26a significantly increased expression of osteogenic and angiogenic markers at both gene and protein level. Using a rat calvarial defect model with a critical size defect, RALA/miR-26a NPs were delivered via an injectable, thermo-responsive Cs-g-PNIPAAm hydrogel to assess the impact on both rate and quality of bone healing. Critical defects treated with the RALA/miR-26a nanoparticles (NPs) had significantly increased bone volume and bone mineral density at 8 weeks, with increased blood vessel formation and mechanical properties. This study highlights the utility of RALA to deliver miR-26a for the purpose of bone healing within an injectable biomaterial, warranting further investigation of dose-related efficacy of the therapeutic across a range of in vivo models. [Display omitted]